Targeting DNA repair as a promising approach in cancer therapy

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

An increased DNA-repair activity in tumour cells has been associated with resistance to treatment to DNA-directed drugs, while defects in DNA repair pathways result in hypersensitivity to these agents. In the past years the unravelling of the molecular basis of these DNA pathways, with a better understanding of the DNA damage caused by different anticancer agents, has provided the rationale for the use of some DNA repair inhibitors to optimise the therapeutic use of DNA-damaging agents currently used in the treatment of tumours. In addition, the possibility to specifically target the differences in DNA repair capacity between normal and tumour cells has recently emerged as an exciting possibility. The present review will mainly cover those approaches that are currently under clinical investigation.

Original languageEnglish
Pages (from-to)1791-1801
Number of pages11
JournalEuropean Journal of Cancer
Volume43
Issue number12
DOIs
Publication statusPublished - Aug 2007

Fingerprint

DNA Repair
DNA
Neoplasms
Therapeutic Uses
Therapeutics
Antineoplastic Agents
DNA Damage
Hypersensitivity
Pharmaceutical Preparations

Keywords

  • Anticancer drugs
  • DNA repair

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Targeting DNA repair as a promising approach in cancer therapy. / Damia, Giovanna; D'Incalci, Maurizio.

In: European Journal of Cancer, Vol. 43, No. 12, 08.2007, p. 1791-1801.

Research output: Contribution to journalArticle

@article{2ea57459e9c7417cac47c1f7e4bb6538,
title = "Targeting DNA repair as a promising approach in cancer therapy",
abstract = "An increased DNA-repair activity in tumour cells has been associated with resistance to treatment to DNA-directed drugs, while defects in DNA repair pathways result in hypersensitivity to these agents. In the past years the unravelling of the molecular basis of these DNA pathways, with a better understanding of the DNA damage caused by different anticancer agents, has provided the rationale for the use of some DNA repair inhibitors to optimise the therapeutic use of DNA-damaging agents currently used in the treatment of tumours. In addition, the possibility to specifically target the differences in DNA repair capacity between normal and tumour cells has recently emerged as an exciting possibility. The present review will mainly cover those approaches that are currently under clinical investigation.",
keywords = "Anticancer drugs, DNA repair",
author = "Giovanna Damia and Maurizio D'Incalci",
year = "2007",
month = "8",
doi = "10.1016/j.ejca.2007.05.003",
language = "English",
volume = "43",
pages = "1791--1801",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "12",

}

TY - JOUR

T1 - Targeting DNA repair as a promising approach in cancer therapy

AU - Damia, Giovanna

AU - D'Incalci, Maurizio

PY - 2007/8

Y1 - 2007/8

N2 - An increased DNA-repair activity in tumour cells has been associated with resistance to treatment to DNA-directed drugs, while defects in DNA repair pathways result in hypersensitivity to these agents. In the past years the unravelling of the molecular basis of these DNA pathways, with a better understanding of the DNA damage caused by different anticancer agents, has provided the rationale for the use of some DNA repair inhibitors to optimise the therapeutic use of DNA-damaging agents currently used in the treatment of tumours. In addition, the possibility to specifically target the differences in DNA repair capacity between normal and tumour cells has recently emerged as an exciting possibility. The present review will mainly cover those approaches that are currently under clinical investigation.

AB - An increased DNA-repair activity in tumour cells has been associated with resistance to treatment to DNA-directed drugs, while defects in DNA repair pathways result in hypersensitivity to these agents. In the past years the unravelling of the molecular basis of these DNA pathways, with a better understanding of the DNA damage caused by different anticancer agents, has provided the rationale for the use of some DNA repair inhibitors to optimise the therapeutic use of DNA-damaging agents currently used in the treatment of tumours. In addition, the possibility to specifically target the differences in DNA repair capacity between normal and tumour cells has recently emerged as an exciting possibility. The present review will mainly cover those approaches that are currently under clinical investigation.

KW - Anticancer drugs

KW - DNA repair

UR - http://www.scopus.com/inward/record.url?scp=34547754492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547754492&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2007.05.003

DO - 10.1016/j.ejca.2007.05.003

M3 - Article

C2 - 17588740

AN - SCOPUS:34547754492

VL - 43

SP - 1791

EP - 1801

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 12

ER -